gabadmin

As researchers continue working around the clock to put together the puzzle pieces needed for better understanding Covid-19 pathology, the disease has further exposed a serious lack of treatments for mental health conditions. In Sweden, biotech Gabather is developing new treatments for CNS diseases, including psychiatric disorders that appear in many

Läs mer

BioStock Studio: Gabather gives clinical trial update

25 mars, 2021 gabadmin

BioStock Studio: Gabather gives clinical trial update – BioStock

Läs mer

FinWire: Aktieportföljen Live 10 Mars

10 mars, 2021 gabadmin

Läs mer

Biostock: Q4 report points to progress in the clinic for Gabather

22 februari, 2021 gabadmin

Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002. Going forward the company will focus on studying the effects of its top candidate on brain activity, which will be a key step in determining dosage of GT-002 to

Läs mer

QA med VD Michael Robin Witt

9 februari, 2021 gabadmin

Kliniska studier Ni väntade er att den slutliga studierapporten för fas 1b skulle bli tillgänglig i slutet av förra året. Årsskiftet är passerat utan vare sig studierapport eller förklaring till varför den är sen. Varför saknas besked ang. detta, får ni inte kommunicera saken eller har ni inte ansett det

Läs mer